Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

Benzinga Newsdesk www.benzinga.com Positive 81.7%

Neg 0% Neu 0% Pos 81.7%

Guggenheim analyst Michael Schmitz maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $42 to $58.